Clinical InvestigationCongestive Heart FailureCirculating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure
Section snippets
Materials and methods
We recruited 88 consecutive patients with advanced HF attending the outpatient HF clinic of the Tel Aviv Sourasky Medical Center. Patients with CHF within New York Heart Association (NYHA) functional classes II-IV were included. The local research ethics committee approved the study protocol and all patients gave written informed consent.
At baseline, patients had a full medical history taken, clinical examination performed, and NYHA class assigned. Patients were followed up every 1 to 3 months
Results
Mean age of the study patients was 72 ± 12 years, their median NYHA was 2.8, and their mean ejection fraction was 38% ± 14%. Sixty-three (72%) of the patients were males. Of the total 88 patients, 72 (82%) were receiving either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 33 (38%) were on spironolactone, 58 (66%) were on β-blockers, and 24 (21%) were receiving digoxin.
Matrix metalloproteinase-2 serum levels significantly correlated with age (r = 0.33, P < .01,
Discussion
We have found that MMP-2, -9, and TIMP-1 serum levels were increased in patients with CHF as compared with control subjects. Levels of MMP-2 but not of the other MMPs or TIMP-1 correlated with the clinical status of the patients exhibited by their NYHA scores. These findings are in line with a recent publication,9 yet partially discordant with a study from Wilson et al10 showing that MMP-2 levels did not differ between patients with CHF and subjects with nonfailing hearts. These apparent
References (13)
- et al.
Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis
Am J Cardiol
(1995) - et al.
Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure
J Card Fail
(2002) - et al.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure. Function, and biochemistry
Circ Res
(2003) Matrix metalloproteinases: regulation and dysregulation in the failing heart
Circ Res
(2002)- et al.
Differential expression of tissue inhibitors of metalloproteinases in the failing human heart
Circulation
(1998) - et al.
Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links
Am J Pathol
(1996)
Cited by (106)
MMP-2 and its implications on cardiac function and structure: Interplay with inflammation in hypertension
2023, Biochemical PharmacologyCadmium exposure induces histological damage and cytotoxicity in the cardiovascular system of mice
2023, Food and Chemical ToxicologyAssociations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort
2022, International Journal of CardiologyCitation Excerpt :Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases and are controlled through tissue inhibitors of metalloproteinases (TIMPs) [49]. MMPs can degrade components of the extra cellular matrix (ECM) including collagens and play and important role in ECM remodelling [50–52]. In rat, canine and ovine models of acute pulmonary embolism pre-treatment with doxycycline -a non-selective MMP inhibitor- reduced RV dilation [52].
Matrix metalloproteinase-2-induced epidermal growth factor receptor transactivation impairs redox balance in vascular smooth muscle cells and facilitates vascular contraction
2018, Redox BiologyCitation Excerpt :Among other MMPs, mounting evidence implicates MMP-2 as a major player in disease processes, particularly in cardiovascular diseases [2,3]. In fact, increased circulating levels of MMP-2 have been associated with worse prognosis in patients with cardiovascular disease [4] and were suggested to predict mortality [5]. Moreover, acutely increasing circulating MMP-2 levels significantly impaired both cardiac and vascular function [6], although the precise mechanisms explaining these findings have not been fully elucidated.
Curcumin in heart failure: A choice for complementary therapy?
2018, Pharmacological ResearchThe application of collagen-related biomarkers in heart failure
2023, Chinese Journal of Laboratory Medicine
- 1
Affiliated to the Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel.